RxDoctor Payments Data

Mark Dickson, MD

Hematology & Oncology · New York, NYNPI 1619121621

Payments from drug & device makers

What this record shows

That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$355,528in research payments, 2019–2025

Across 13 payments — averaging $27,348 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$189K
  • Sanofi US Services Inc.$77K
  • Sumitomo Pharma America, Inc.$65K
  • Aadi Bioscience, Inc.$24K

How this compares

$0 in reported general payments places this provider in the 0th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York →

Medicare billing

Part B allowed, 2024
$45,129
Medicare patients
142
Services billed
397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib17$260,083
Oxycodone Hcl14$130

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →